News

Pfizer and Debiopharm have entered into a co-development agreement to conduct a phase 3 trial of Tremelimumab (CP675,206), a fully human anti-CTLA4 monoclonal antibody, for the treatment of

The company claims that Actemra is the first interleukin-6 (IL-6) receptor-inhibiting monoclonal antibody approved to treat RA, and may be used alone or in combination with methotrexate or

As part of EPA’s efforts to enhance chemicals management under the Toxic Substances Control Act (TSCA), it has released action plans on four chemicals. EPA administrator, Lisa Jackson,

Varlix, with expertise in neuro and spine surgery, has been introducing medical devices and capital equipment to the Mexican surgical marketplace on a regular basis. Misonix said that

Reportedly, the phase 1 trial is an open-label, dose-escalation study evaluating the safety and tolerability of TL32711 in adults with solid tumors or lymphoma refractory to standard therapies.

The study is being conducted by Dr. Rhonda Voskuhl, director of UCLA Multiple Sclerosis Program, UCLA Department of Neurology. Investigators will administer Trimesta along with glatimer acetate (Copaxone),

The Cystinosis Research Foundation (CRF) of Irvine, California, has awarded $1.75m in 11 new grants to researchers in the US, Canada, Belgium and Italy, who are working to

FX125L is the lead drug candidate in this class, while other BSCIs have been identified as back up molecules or as candidates for development as topical anti-inflammatory agents.

Chennai-based Orchid Chemicals & Pharmaceuticals has received atentative approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application (NDA) for Memantine Hydrochloride tablets